<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A47BB0A4-29B1-46AB-A0A8-0F7497EE8E5D"><gtr:id>A47BB0A4-29B1-46AB-A0A8-0F7497EE8E5D</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:surname>Wheatley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F6D14360-DA4F-4D4F-9044-8212DEA5BDF8"><gtr:id>F6D14360-DA4F-4D4F-9044-8212DEA5BDF8</gtr:id><gtr:firstName>Alan Kenneth</gtr:firstName><gtr:surname>Burnett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9901427"><gtr:id>CEF10475-8935-4946-A0AF-36E7F99315A9</gtr:id><gtr:title>Acute Myeloid Leukaemia Trial 15 (AML 15)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9901427</gtr:grantReference><gtr:abstractText>The cure rate of patients with AML under 60 years is improving as a result of increasing intensity of treatment (1980 - 12%: 2000-53%). In this trial two induction combinations (H-DAT and FLAG-Ida) will be compared. H-DAT was the better arm from the recent MRC Trial and FLAG-Ida is widely used but never compared in a randomised trial. The trial will try to refine treatment to prevent relapse. The best chemotherapy arm of the current MRC trial will be compared with high dose Cytosine-Arabinoside (Ara-C) which is widely used in the USA. Two dose levels of Ara-C will be tested. It is not clear how many total courses of treatment are needed. This trial will compare 4 vs 5 courses and will add to the experience of the 4 vs 5 course comparison from the present AML12 trial. A new agent which is a drug attached to an antibody to specifically target leukaemia cells has recently been developed. This trial will assess the value of adding this immunoconjugate to both induction and/or consolidation treatment.

About 15% of cases are Acute Promyelocytic Leukaemia. It may be possible to cure a high proportion of cases (~80%) as done in the current AML12 trial, but with much less intensive chemotherapy developed by the Spanish Group. We will compare the MRC versus the Spanish approach. We anticipate a recruitment of 550 patients &amp;lt;60 years per annum from 200 centres in the UK.</gtr:abstractText><gtr:technicalSummary>This is a major randomised trial in Acute Myeloid Leukaemia in patients under 60 years old to be conducted in 200 institutions in the UK and several abroad. In induction phase H-DAT (derived from the current MRC AML12 Trial) will be compared with FLAG-Ida which has never been subjected to randomised comparison. In addition the value of immunoconjugate (CMA676/Myelotarg - a humanised anti CD33 linked to Calicheamycin) given or not on day 1 of treatment. High risk patients will leave the trial and enter the MRC AML-HR trial. In consolidation patients who have a matched donor will receive a transplant as course 3. Patients &amp;lt;35 years will receive a conventional allograft. In patients 35-45 will have a choice of a conventional allograft or a non-ablative minigraft: patients over 45 will receive a minigraft. Only standard risk patients will be transplanted. The value of a transplant will be compared with 4 or 5 courses of chemotherapy on a donor versus no donor analysis. Patients not allocated to transplant will enter a comparison of MRC consolidation (MACE + MidAc) versus high dose Ara-C. In addition 2 doses of Ara-C (3g vs 1?g) will be compared. With each course of consolidation chemotherapy patients will be randomised to receive immunoconjugate (CMA-676/Myelotarg) or not. Finally patients who have completed 4 courses of chemotherapy will be randomised to receive a 5th course (1g Ara-C) or not.

Patients with the Acute Promyelocytic subgroup will enter a comparison of the established MRC approach with the Anthracycline based Spanish approach with economic and quality of life comparison.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1378797</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open days and patient association</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>5CB5141E-206D-4EEC-9F66-27196DEED5B1</gtr:id><gtr:impact>Presented at open days and patient association

Improved knowledge of Leukaemia trials activity and research amongst patients, carers and general public.</gtr:impact><gtr:outcomeId>RkvrBe5rsL2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Established as standard of care in the UK and Denmark</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>53ED49B5-5575-402E-83D3-920BEEFEACFE</gtr:id><gtr:impact>Established as standard of care in the UK and Denmark</gtr:impact><gtr:outcomeId>No2CzquUnSW</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>02728DAE-F77A-41BE-821A-6E338FC98BF6</gtr:id><gtr:title>Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd6234818e384ba39a1a4d1aa05c098"><gtr:id>cdd6234818e384ba39a1a4d1aa05c098</gtr:id><gtr:otherNames>Burnett AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5a327ca86acb48.93672265</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9901427</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>046212FE-8853-46F0-B1E7-3CBA4770A15F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>